Amendments to the Specification

Please delete the Abstract and replace it with the following:

A method of inhibiting NF-κB activation in a mammal including a human, which comprises the step of administering an effective dose of a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:



(I)

~~A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused-polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is ① a fused-polycyclic heteroaryl group wherein the ring which binds directly to –CONH– group in the formula (I) is a benzene ring, ② unsubstituted thiazol-2-yl group, or ③ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula –O-A wherein A has the same meaning as that defined above and the group represented by formula –CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula –O-A wherein A has the same meaning as that defined above and the group represented by formula –CONH-E wherein E has the same meaning as that defined above.~~